Skip to content

Investigation of the effect of pentoxifylline on the prevention of radio contrast nephropathy

Evaluation of the effect of oral pentoxifylline on prevention of radiocontrast nephropathy in patient that undergone angiographye

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20161219031464N4
Enrollment
192
Registered
2020-09-08
Start date
2020-02-20
Completion date
Unknown
Last updated
2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney disorders caused by contrast material following angiography.

Interventions

Intervention 1: Intervention group: In this group, they receive normal saline at a dose of one cc per kilogram of body weight and pentoxifylline (400 mg orally every 8 hours) for 12 hours before and

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: The criteria for entering the study include patients who are candidates for angiography with cardiac service indications and will be admitted to cardiac service.

Exclusion criteria

Exclusion criteria: patients with stage 5 CKD, kidney transplantation, patients with renal insufficiency with a GFR below 30 patients with a history of allergy to pentoxifylline according to history.

Design outcomes

Primary

MeasureTime frame
Serum creatinine and creatinine clearance. Timepoint: Serum creatinine and clearance creatinine of patients will be tested the day before and the next day and 48 hours later. Method of measurement: blood and urine sample examination.;C reactive protein. Timepoint: The day before and after angiography. Method of measurement: Blood test.;Proteinuria. Timepoint: The day before and after angiography. Method of measurement: Urine examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Yassari

Shahid Beheshti University of Medical Sciences

fa.yassari@gmail.com+98 21 2712 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026